Walewski J, et al. - In this phase IV study including 60 patients (aged ≥ 18 years) with CD30-positive relapsed/refractory Hodgkin lymphoma (HL), a history of ≥ 1 prior systemic chemotherapy regimen, who were considered unsuitable for stem cell transplant (SCT)/multi-agent chemotherapy, researchers assessed the impact of brentuximab vedotin (1.8 mg/kg intravenously once every 3 weeks) on overall response rate (ORR) per independent review facility (IRF) as well as duration of response (DOR), progression-free survival (PFS) per IRF, overall survival (OS), quantity going on to SCT, and safety. The ORR was 50%, with 12% having CR, 47% proceeded to SCT, and estimated OS rate was 86% at 12 months. Peripheral neuropathy (35%), pyrexia (18%), diarrhea, and neutropenia (each 10%) were documented as the most common adverse events. Based on the findings, an excellent activity of brentuximab vedotin as well as its safety profile consistent with known toxicities was evident. Furthermore, brentuximab vedotin may act as a bridge to SCT and thereby allow this potentially curative treatment to be received by high-risk patients who achieve suboptimal response to frontline/salvage chemotherapy/radiotherapy.